Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review
{{output}}
Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced driver-negative non-small cell lung cancer (NSCLC). However, targeted therapy remains the preferred treatment for advanced driver-positive NSCLC, including case... ...
